Spike Protein Evolution and ACE2 Binding Dynamics in Emerging Coronaviruses

Introduction

Coronaviruses (CoVs) are enveloped, positive-sense RNA viruses that infect a wide range of avian and mammalian hosts. The spike (S) glycoprotein, a class I fusion protein, mediates host cell entry by binding to specific receptors and facilitating membrane fusion. In many coronaviruses, including those from the Betacoronavirus genus, the primary receptor is angiotensin-converting enzyme 2 (ACE2) [1, 2]. The receptor-binding domain (RBD) within the S1 subunit undergoes continuous evolutionary pressure from host immune responses and receptor compatibility constraints [3, 4]. Understanding the molecular determinants of RBD-ACE2 interactions is critical for predicting zoonotic spillover risk and designing veterinary diagnostic assays [5, 6]. This article reviews computational approaches to studying spike protein evolution, focusing on RBD mutations that alter ACE2 binding affinity, and highlights key mutations observed in emerging coronaviruses from bat, pangolin, and other animal reservoirs.

Spike Protein Structure and RBD Architecture

The coronavirus spike protein is a trimeric glycoprotein with each protomer composed of S1 and S2 subunits. The S1 subunit contains the N-terminal domain (NTD) and the RBD, while the S2 subunit houses the fusion machinery [7, 8]. The RBD adopts a core structure stabilized by disulfide bonds and a receptor-binding motif (RBM) that directly contacts ACE2 [9, 10]. In sarbecoviruses, the RBD can adopt two conformational states: a "standing" (up) state that exposes the RBM for receptor binding and a "lying" (down) state that shields the RBM from antibody recognition [11, 12]. Glycan shielding, mediated by N-linked glycosylation sites on the spike surface, further modulates both receptor accessibility and immune evasion [11, 7]. Disruption of these glycans can impair spike folding and reduce infectivity [8].

The RBD-ACE2 interface is characterized by a network of hydrogen bonds, salt bridges, and hydrophobic contacts [9, 10]. Key contact residues in the RBM include positions 484, 486, 493, 498, 501, and 505 (SARS-CoV-2 numbering), which are hotspots for mutation in emerging variants [3, 13, 4]. Deep mutational scanning studies have systematically mapped the fitness landscape of these residues, revealing epistatic interactions that constrain or promote certain amino acid substitutions [3, 13, 4]. For example, the N501Y mutation enhances ACE2 binding by introducing a new aromatic stacking interaction with Y41 of ACE2 [10]. Similarly, E484K alters electrostatic complementarity and can reduce antibody neutralization [13, 14].

Computational Approaches to Studying RBD-ACE2 Interactions

Computational virology employs a suite of biophysical and bioinformatic methods to predict and analyze spike protein evolution. Key approaches include molecular dynamics (MD) simulations, free energy perturbation (FEP) calculations, phylogenetic analysis, and machine learning-based variant effect prediction [15, 12, 16, 17].

Molecular Dynamics Simulations

MD simulations model the atomic-level motions of the RBD-ACE2 complex over time, providing insights into binding kinetics, conformational flexibility, and the impact of mutations on stability [15, 12]. All-atom simulations using explicit solvent force fields (e.g., CHARMM, AMBER) can capture subtle changes in hydrogen bonding networks and solvent accessibility [15]. Coarse-grained models enable longer timescale simulations of spike trimer dynamics, including RBD opening and closing [12]. These simulations have revealed that mutations such as N501Y and K417N alter the conformational ensemble of the RBM, shifting the equilibrium toward higher-affinity states [15, 10].

Free Energy Perturbation Calculations

FEP calculations estimate the change in binding free energy (ΔΔG) upon mutation, allowing quantitative ranking of variant effects on ACE2 affinity [12, 18]. Alchemical FEP methods, combined with enhanced sampling techniques, have been used to predict the impact of single and combinatorial mutations in the RBD [12, 18]. For instance, FEP studies correctly predicted that the Q498R mutation, when combined with N501Y, synergistically enhances ACE2 binding [10]. These calculations are computationally intensive but provide high-resolution energetic landscapes that complement experimental deep mutational scanning data [3, 13].

Phylogenetic and Evolutionary Analysis

Phylogenetic reconstruction of spike sequences from diverse coronavirus lineages reveals patterns of convergent evolution and adaptive selection [19, 10, 20]. Maximum likelihood and Bayesian methods can detect positively selected sites (e.g., dN/dS > 1) in the RBD, indicating ongoing host-driven adaptation [19, 20]. Stringent selection pressures have driven convergence toward Omicron-like RBM motifs in multiple sarbecovirus lineages, suggesting a common evolutionary trajectory for ACE2 adaptation [10]. Phylogenetic analysis of bat and pangolin coronaviruses has identified RBD sequences with pre-existing affinity for human ACE2, highlighting zoonotic potential [10, 1, 2].

Machine Learning and Deep Learning

Machine learning models, including random forests, gradient boosting, and deep neural networks, have been trained on large-scale mutational scanning data to predict variant effects on binding and immune escape [16, 17, 21]. These models incorporate sequence, structural, and evolutionary features to generalize beyond experimentally tested mutations [16, 21]. Deep mutational learning approaches can also predict polyclonal antibody escape profiles, aiding in antigenic characterization of emerging variants [17]. Such predictive tools are valuable for real-time surveillance of animal coronaviruses and for prioritizing variants for experimental testing [5, 16].

The following Mermaid diagram illustrates a typical computational workflow for predicting spike protein evolution and ACE2 binding dynamics.

flowchart TD
    A[Spike Sequence Data from Surveillance], > B[Phylogenetic Analysis & Positive Selection Detection]
    B, > C[Identify RBD Mutations of Interest]
    C, > D[Structural Modeling (e.g., AlphaFold, Homology Modeling)]
    D, > E[Molecular Dynamics Simulations of RBD-ACE2 Complex]
    E, > F[Free Energy Perturbation Calculations]
    F, > G[Predict ΔΔG and Binding Affinity Changes]
    C, > H[Deep Mutational Scanning Data (Experimental)]
    H, > I[Train Machine Learning Models]
    I, > J[Predict Variant Effects on Binding & Immune Escape]
    G, > K[Integrate Predictions for Risk Assessment]
    J, > K
    K, > L[Inform Diagnostic Assay Design & Surveillance Priorities]

Key Mutations and Their Biophysical Effects

Numerous RBD mutations have been characterized for their impact on ACE2 binding affinity and immune evasion. Table 1 summarizes several key mutations identified in emerging coronaviruses, their structural context, and functional consequences.

Table 1. Selected RBD Mutations and Their Effects on ACE2 Binding and Immune Evasion

Epistatic interactions between these mutations are critical for understanding overall fitness [3, 4]. For example, the combination of N501Y and Q498R produces a greater-than-additive increase in ACE2 binding [10]. Similarly, the E484K mutation can be deleterious in some genetic backgrounds but beneficial in others, depending on compensatory changes elsewhere in the spike [4, 14]. Intra-host recombination can also generate novel epistatic combinations, as demonstrated in temperature-dependent adaptation studies [15].

Phylogenetic Analysis and Zoonotic Spillover

Phylogenetic analyses of coronaviruses from bats, pangolins, and other wildlife have revealed extensive diversity in spike sequences, with many lineages possessing RBDs capable of binding ACE2 from multiple species [10, 1, 2]. The discovery of a merbecovirus with potential ACE2 usage in France underscores the ongoing risk of novel receptor-binding phenotypes emerging in animal populations [1]. Heart-nosed bat alphacoronaviruses have been shown to use human CEACAM6 for entry, illustrating alternative receptor usage beyond ACE2 [2]. These findings highlight the need for broad surveillance of spike-receptor interactions across diverse coronavirus genera.

Computational prediction of cross-species receptor binding dynamics is a key area of research [10, 1]. Structural modeling and docking simulations can assess whether a given animal coronavirus RBD can accommodate ACE2 orthologs from humans, livestock, or companion animals [10]. Such predictions are essential for prioritizing zoonotic risk assessments and for designing diagnostic assays that remain effective as viruses evolve [5, 6]. For example, the emergence of the JN.1 lineage and its sublineages (e.g., NB.1.8.1) has been associated with accelerated fitness gains driven by RBD mutations that enhance both ACE2 binding and immune evasion [19, 20, 22].

Implications for Veterinary Diagnostics and Surveillance

The continuous evolution of coronavirus spike proteins poses challenges for molecular diagnostic assays, particularly those targeting conserved regions of the spike gene [5, 23]. Mutations in primer or probe binding sites can lead to false-negative results, necessitating periodic assay redesign [5]. Genomic surveillance of animal coronaviruses, including those from poultry (e.g., infectious bronchitis virus), swine (e.g., porcine epidemic diarrhea virus), and wildlife, is essential for maintaining diagnostic accuracy [24, 5, 23]. Whole-genome sequencing and phylogenetic monitoring can detect emerging variants before they compromise assay performance [23, 6, 19].

Computational tools that predict the impact of spike mutations on diagnostic target regions can guide proactive assay updates [5]. Additionally, understanding the antigenic evolution of spike proteins informs the design of serological tests and vaccines for veterinary use [25, 26, 27]. Nanoparticle vaccines displaying chimeric RBDs have shown broad neutralization across multiple coronaviruses, suggesting a path toward pan-coronavirus veterinary vaccines [25, 27]. The use of broadly cross-reactive antigens can mitigate the effects of immune imprinting and antigenic drift [28].

Conclusion

Spike protein evolution in emerging coronaviruses is driven by a complex interplay of receptor binding optimization and immune evasion. Computational approaches, including molecular dynamics simulations, free energy perturbation, phylogenetic analysis, and machine learning, provide powerful tools for dissecting these dynamics at atomic resolution. Key mutations such as N501Y, E484K, and Q498R have been shown to modulate ACE2 binding affinity and antibody escape, often through epistatic interactions. Phylogenetic surveillance of animal coronaviruses remains critical for early detection of variants with zoonotic potential. Integrating computational predictions with experimental validation will enhance our ability to anticipate viral emergence and maintain effective veterinary diagnostic and control measures.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

References

[1] Rieu O, Descorps-Declère S, Dufau A, et al. Detection of a Merbecovirus with potential ACE2 usage in France. Emerg Microbes Infect. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42025593/

[2] Gallo G, Di Nardo A, Lugano D, et al. Heart-nosed bat alphacoronaviruses use human CEACAM6 to enter cells. Nature. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42020746/

[3] Taylor AL, Starr TN. Deep mutational scanning of recent SARS-CoV-2 variants highlights changing amino acid preferences within epistatic hotspot residues. PLoS Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42330076/

[4] Moulana A, Dupic T, Desai MM. Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 spike protein. Mol Biol Evol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42142336/

[5] Gupta S, Chaudhary A, Bhatnagar S. SARS-CoV-2 Evolution and Its Implications for RT-PCR Diagnostic Performance. J Med Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42312714/

[6] Liu J, Zhang Y, Yang L, et al. Genomic insights into SARS-CoV-2 evolution in Yantai, China after the adjustment of the dynamic zero-COVID policy in 2023. PeerJ. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42079734/

[7] Guo D, Yu S, Ma K, et al. Concanavalin A targets phylogenetically conserved N-linked glycans on coronavirus spike proteins for broad-spectrum antiviral activity. J Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42037405/

[8] Kong W, Zhang J, Song Y, et al. Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. J Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41910405/

[9] Smatti MK, Al-Khatib H, Suleman M, et al. Functional and structural characterization of the SARS-CoV-2 spike N481K mutation. Arch Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42243594/

[10] Shoshany A, Tian R, Padilla-Blanco M, et al. Stringent selection drives convergence toward omicron-like SARS-CoV-2 receptor-binding motifs. Nat Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42034607/

[11] Kumar A, Yadav AJ, Tripathi T, et al. Glycan shielding and epitope reorganization drive sotrovimab resistance in SARS-CoV-2 Omicron variants. Arch Biochem Biophys. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42128042/

[12] Alshahrani M, Gatlin W, Ludwick M, et al. Mechanisms of Binding and Immune Escape Resistance for Broadly Neutralizing Antibodies Targeting Distinct Conserved SARS-CoV-2 Spike Epitopes: A Hierarchical Approach Integrating Mutational Profiling and Energy Landscape Analysis. Int J Mol Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42123600/

[13] Shao C, Yang L, Xiao C, et al. Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. Emerg Microbes Infect. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42324717/

[14] Li P, Zheng Y-M, Liu S-L. Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants. J Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42117695/

[15] Altaf M, Kin Cheng MT, González-Vázquez LD, et al. SARS-CoV-2 intra-host recombination promotes epistatic spike interactions and temperature-dependent adaptation. Cell Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42213788/

[16] Nasir A, Lee D, Avena LE, et al. Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants. J Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42037411/

[17] Shlesinger D, Sadilek V, Minot M, et al. Dissecting serum polyclonal antibody escape to SARS-CoV-2 variants by deep mutational learning. Cell Rep Methods. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42030951/

[18] Alshahrani M, Gatlin W, Ludwick M, et al. Frustration Landscapes of Broadly Neutralizing SARS-CoV-2 Spike Antibodies Targeting Conserved Epitopes Reveal Energetic Logic of Escape-Proof and Escape-Prone Mechanisms. bioRxiv. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41959354/

[19] Puenpa J, Vichaiwattana P, Aeemjinda R, et al. Genomic Characterization and Evolutionary Dynamics of SARS-CoV-2 Lineage NB.1.8.1 in Thailand, 2025. Viruses. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42043239/

[20] Lei ZY, Jin QT, Zhang XM, et al. Genomic-epidemiological analysis of 15 million SARS-CoV-2 genomes reveals accelerated fitness gain of JN.1 lineage. Virol Sin. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41962740/

[21] Caraway J, Sung W. Predicting the evolution and persistence of COVID-19 using context-dependent polymorphisms. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41936602/

[22] Sharma S, Manikyam HK. Emergence of SARS-CoV-2 omicron subvariant NB.1.8.1 in India: Genomic evolution, transmission patterns, and public health implications. Indian J Med Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41934416/

[23] Yang H, Wang X, Zhang L, et al. Comprehensive whole-genome characterization of SARS-CoV-2 strains in Jining China 2024-2025. Front Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42182013/

[24] Williman J, Tomas G, Vagnozzi A, et al. Genome-Wide Analysis of Serial Passage of the Infectious Bronchitis Virus Reveals Evolutionary Dynamics Underlying Attenuation and Immunogenicity. Vaccines (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42347589/

[25] Halfmann PJ, Duffy A, Wee A, et al. Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins. Biotechnol Prog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42290307/

[26] Turner SA, Olivier J, Ellis ML, et al. Antigenic characterization of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal models. bioRxiv. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42244675/

[27] Wan D, Li L, Feng H, et al. A self-assembled nanoparticle vaccine displaying chimeric and trimeric RBD-HRC elicits broad-spectrum neutralizing antibodies against multiple coronaviruses. Microbiol Spectr. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41910140/

[28] De Chiara A, Giachino C, Pirillo MF, et al. Broadly cross-reactive mRNA COVID-19 vaccine encoding trimeric RBDs and NSP12 mitigates immune imprinting. Mol Ther Nucleic Acids. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42023032/

[29] Diener C, Urschel R, Bronder S, et al. Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection. Eur J Immunol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42334082/

[30] Bu F, Saxena D, Turner-Hubbard H, et al. Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape. PLoS Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42149970/

[31] Uzer F, Erendor F, Sanlioglu S. SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design. Rev Med Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42047168/

[32] Mahdi M, Al-Muffti AS, Linkner TR, et al. Retrospective neutralization analysis of SARS-CoV-2 variants in early pandemic sera. Front Immunol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42004965/

[33] Korobkova AI, Favorskaya IA, Shuliakova IV, et al. Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants. Front Immunol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41948332/

[34] Xiu R, Wang Y, Cai W, et al. Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors. J Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41910260/

[35] Ermolaeva EA, Zyrina AN, Sirazova DI, et al. Insertion in the N-Terminal Domain of the SARS-CoV-2 Spike Glycoprotein Affects Antibody Recognition and Phenotypic Properties. Viruses. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41902185/